Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Locoregional Delivery of Engineered NK Cells in Recurrent Glioblastoma
NCT07579208Phase 1Recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Aug 2026
- Primary completion
- Jul 2028
- Countries
- 1
01
Overview
Phase 1, open-label trial in glioblastoma (GBM) (3 arms), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Safety and adverse events at 1 year. Started Aug 2026; status: recruiting.
02
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT07579208.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07579208.